Clare specialises in corporate and securities law, with a particular focus on equity capital markets, venture capital and M&A.
She has experience in cross-border and domestic corporate transactions including advising on equity fundraisings, private financing and investment transactions, regulated and private M&A, securities regulatory and ASX compliance issues, ESOPs and other general corporate matters.
She regularly acts for companies and investors in the healthcare, medical device and biotechnology sector, as well as the technology industry more broadly. Clare also regularly represents early and growth stage companies and venture capital firms that invest in them.
Clare also has significant experience advising US clients doing business in Australia and Australian clients doing business in the US, including having acted for a number of US companies listed on ASX.
Advised on its 2023 initial public offering and listing on the ASX.
Advised on its 2021 A$110 million IPO and ASX listing and its placement and SPP in 2023.
Advised on its placement and share purchase plan which raised A$35 million in 2023.
Advised on its non-renounceable entitlement offer and director placement in 2023.
Advised on its pre-IPO financing and IPO and ASX listing in 2019 and follow-on capital raisings in 2020 -2024 (including its recent ANREO).
Advised Laybuy Group Holdings Limited on its $80M IPO and ASX-listing in 2020, and its placement and SPP in 2021.
Advised on its renounceable entitlement offer to raise up to A$15.5 million.
Advised lead manager on multiple capital raisings in the energy and resources sector.
Advised on its Series B, Series C and Series D financings.
Advised on its investment in ImmVirX.
Advised on its Series A financing in 2021 and 2023.
Advised on various VC investments.
Advised on its investment in Xefco.
Advised on its convertible note investment in HealthEngine.
Advised on convertible note financings in 2019 and 2020.
Advised on its pre-IPO funding round and proposed IPO.
Advised on its 2022 pre-IPO funding rounds.
Advised Simplify Medical on its acquisition by NuVasive, Inc. for US$150 million plus additional milestone payments.
Advised on StraxCorp’s merger with Curvebeam, LLC.
Advised on infant formula joint venture with Bega Cheese.
Advised on redomicile to Bermuda via scheme of arrangement.
Advice on implementation of management equity plan.
Advice on equity incentive plans for various portfolio companies.
Advised on ZEPO plan.
Advice on equity incentive plans.
The ASX is likely to introduce a series of new measures in 2024 aimed at streamlining aspects of the IPO listing process, as outlined in a recent adviser briefing.
From 1 October, we expect to see significant changes in the way that companies offer equity to their Australian personnel. For many businesses, new rules in the Corporations Act significantly...
ASIC and ASX have both announced temporary changes to their respective regulatory regimes to facilitate capital raisings for listed entities in response to the economic impact of COVID-19.